Acute leukaemia types: Difference between revisions
From haematologyetc.co.uk
No edit summary |
No edit summary |
||
Line 71: | Line 71: | ||
|colspan="1" style = "font-size:90%; color:black;" |'''[[CD13]]''' | |colspan="1" style = "font-size:90%; color:black;" |'''[[CD13]]''' | ||
|colspan="1" style = "font-size:84%;"|A good lineage marker for AML that is acquired a little later in differentation than CD117 or CD33; expression of CD13 is often higher than CD33 in AML with monocytic differentiation. | |colspan="1" style = "font-size:84%;"|A good lineage marker for AML that is acquired a little later in differentation than CD117 or CD33; expression of CD13 is often higher than CD33 in AML with monocytic differentiation. | ||
|- | |||
|] | |||
<span id="anchor_1"></span>. | |||
<div style="width: 100%; border: 1px solid black; font-size:100%"> | |||
{| class="wikitable" style="color:black; background-color:#ffffff;" cellpadding="0" | |||
!colspan="2" <span style="font-size:90%; colour:white; text-align:center; border: 1px solid black; background:pale gray">|'''MARKERS USEFUL TO CONFIRM MYELOID LINEAGE OR DIFFERENTIATION'''</span><span style="font-size:90%; text-align:left; background:white"> | |||
|- | |||
|colspan="2" style = "font-size:90%; color:black; background:#ddeee1" |'''Frequently expressed "general" markers of myeloid lineage''' | |||
<div class="mw-collapsible mw-collapsed" data-expandtext="Click for explanation" data-collapsetext="Hide explanation"> | |||
<div class="mw-collapsible-content"> | |||
<span style="font-size:90%;></br>These markers may be considered the most frequent set of markers expressed by AML. Having said that the expression of any single marker is not required for the diagnosis of AML and it is recognised that ('''excluding MPO'''), and each may be expressed by cells of ALL. General concepts: | |||
* Expression of MPO is lineage defining and should indicate AML (or MPAL if lymphoid lineage also confirmed) | |||
* In the absence of markers suggesting alternative lineage any of the remaining markers (CD117, CD33, CD13) may (alone) be used to support a diagnosis of AML | |||
* Expression of one or more of CD117, CD33, CD13 markers on otherwise typical ALL is allowed and does not change lineage assignment | |||
</br> | |||
</span> | |||
</div></div></div> | |||
|- | |- | ||
!colspan="2" style = "font-size:90%; background:#ddeee1"|Confirmatory markers of AML or markers of subtype | !colspan="2" style = "font-size:90%; background:#ddeee1"|Confirmatory markers of AML or markers of subtype |
Revision as of 18:35, 26 July 2023
Sections
- Markers of "primitive nature": go to section
- Core markers of most cases: go to section
- Aberrant markers often seen: go to section
- Notes 1: specific subtypes: go to section
- Notes 2: ambiguous lineage go to section
(note: for further information on any marker or section click the blue highlighted text)
.
MARKERS USEFUL TO CONFIRM PRIMITIVE NATURE OF BLAST CELLS | |
---|---|
Useful markers of primitive nature
(1) Typically AML blasts have low CD45 expression and cause low side scatter. This means that they form a relatively uniform and distinctive population that is clearly separate from that of lymphocytes on CD45/SSc plots (for further details see this section). It is important to realise however also not all AML cases may fit this pattern low CD45/low SSc pattern - particularly APL and monocytic AML. | |
CD45 | A marker expressed by all leukocytes and their precursors. In AML expression is characteristically "weak" i.e. significantly less intense than normal lymphocytes or monocytes. In monocytic AML expression may be stronger. |
CD34 | Frequently expressed by AML blast cells (40-80% of cases) - most often in less differentiated forms of AML. Expression is also seein frequently (and often more strongly) in ALL |
Other markers that may be associated with primitive nature in AML | |
In the context of a proven AML diagnosis a number of markers may be expressed that are considered to predominantly reflect their primitive nature. Some of these are more frequently associated with lymphoid disorders, but providing other criteria for AML are met their presence does not change lineage assignment. These include TDT, CD7, other? |
.
MARKERS USEFUL TO CONFIRM MYELOID LINEAGE OR DIFFERENTIATION | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Frequently expressed "general" markers of myeloid lineage
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
MPO | A lineage-defining marker in AML when expressed (around 80% of cases). More frequent in cases with granulocytic maturation. When detected by flow cytometry is diagnostic of myeloid differentiation (either AML or MPAL) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CD117 | An early marker of myeloid lineage, seen in up to 80% of AML and vauable in recognising more primitive differentaiion forms (note that aberrant expression is seen in up to 20% of ALL cases) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CD33 | A good marker for AML, particularly for those cases with granulocytic maturation, CD33 is often less strongly expressed in AML with monocytic dfferentiation and strongly expressed in APL. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CD13 | A good lineage marker for AML that is acquired a little later in differentation than CD117 or CD33; expression of CD13 is often higher than CD33 in AML with monocytic differentiation. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
]
.
.
.
|